The retail of Chinese patent medicines for cardiovascular and cerebrovascular diseases will break through 12 billion, and multi-brands will rise by more than 30%

 Cardiovascular drugs are drugs used to treat cardiovascular system diseases, including lipid-regulating drugs, anti-heart failure drugs, anti-arrhythmic drugs, anti-hypertensive drugs, anti-angina drugs and other chemical drugs
.
In addition, it also includes Chinese patent medicines such as Compound Danshen Dripping Pills, Suxiao Jiuxin Pills, and Tongxinluo Capsules
.
It is understood that cardiovascular and cerebrovascular diseases have become one of the common diseases of the elderly.
As the aging population intensifies, the market demand for related drugs will continue to rise
.
Traditional Chinese medicine has the characteristics of "multiple targets, multiple effects, and low side effects".
Compared with western medicine, it has advantages in preventing and treating cardiovascular and cerebrovascular diseases
.
In recent years, with the increase in the demand for cardio-cerebrovascular drugs, the field of cardio-cerebrovascular Chinese patent medicines has ushered in huge development opportunities
.
For example, according to related data, in 2021, it is expected that the sales of the Chinese city's physical pharmacy terminal cardio-cerebrovascular patent medicine market will exceed 12 billion yuan
.
From the perspective of sales growth, the growth rate of brands such as Kunyao Group's Xuesaitong Soft Capsule, Beijing Tongrentang Tongrentang Pharmaceutical's Angong Niuhuang Pill, and Beijing Peking University Weixin Bio's Xuezhikang Capsules will all exceed 30%
.
Among them, Angong Niuhuang Pill, a large variety of Chinese city entity pharmacies’ terminal cardio-cerebral vascular Chinese patent medicines, has seen rapid sales growth in recent years.
For example, the sales of the drug exceeded 2 billion yuan in 2019, and it is expected to exceed 3 billion yuan in 2021.
Off
.
According to the industry, China's cardiovascular and cerebrovascular Chinese medicine market is currently in a stage of free competition.
It is expected that the cardiovascular and cerebrovascular Chinese medicine market will continue to grow rapidly in the future, or maintain a double-digit annual growth rate
.
At the same time, the cardiovascular and cerebrovascular Chinese medicine industry is gradually moving from immature to maturity, and continues to grow and develop.
By 2026, the market size of Chinese traditional medicine for cardiovascular and cerebrovascular diseases is expected to reach 185.
4 billion yuan
.
In the face of huge market opportunities, some domestic Chinese patent medicine companies have also continued to expand their layout
.
For example, Buchang Pharmaceutical said, it started with Chinese patent medicine for cardiovascular and cerebrovascular since its establishment, and successively developed Naoxintong Capsules, Wenxin Granules, Danhong Injection, and cultivated them into mature varieties that have passed long-term market testing
.
At the same time, drugs in the field of cardiovascular and cerebrovascular have also brought huge benefits to enterprises
.
For example, in the first half of 2021, the six core products of Naoxintong Capsules, Wenxin Granules, Danhong Injection, Guhong Injection, Compound Brain Peptide Ganglioside Injection, and Compound Tretide Injection will bring a total of six core products to Buchang Pharmaceutical 4.
427 billion yuan in sales revenue
.
In the field of cerebrovascular, the recent application for the listing of the new drug Naoshang Lesheng Granules of Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng 1.
1 has been accepted by the CDE
.
It is reported that the drug has the effects of invigorating qi and nourishing blood, invigorating the brain and resuscitating, removing blood stasis and dredging collaterals.
It is suitable for the treatment of craniocerebral trauma and the weakness of qi and blood, brain damage, stasis and meridian paralysis caused by craniocerebral surgery.
Disease
.
In addition, Xinlitai has 8 innovative drugs under development in the field of cardiovascular and cerebrovascular drugs, and its central cerebrovascular drug SAL0104 capsule, a new class 1 drug, has been approved by the State Food and Drug Administration to carry out clinical trials
.
The drug is a coagulation factor XIa inhibitor, and its intended development indication is the prevention and treatment of thrombotic diseases
.
Traditional Chinese medicine has shown its advantages in the field of cardiovascular and cerebrovascular treatment, and it is the cradle of domestically produced heavy varieties.
At the same time, the growth rate of Chinese patent medicine for cardiovascular and cerebrovascular is significantly higher than that of chemical medicine
.
For example, the main dosage forms of traditional Chinese medicine for cardiovascular and cerebrovascular diseases include injections, capsules, pills, and tablets.
According to the relevant data of hospital terminals and retail terminals in 2020, the retail value of injections will reach 38.
785 billion yuan, accounting for 51%
.
In the future, with the acceleration of the aging process, there will be greater market space in the field of Chinese patent medicines for cardiovascular and cerebrovascular diseases
.